Genmab Reports Strong First‑Half Performance and Raises Annual Guidance
Genmab A/S, a Danish biotechnology company listed on the OMX Nordic Exchange Copenhagen, announced its financial results for the first half of 2026 on 6 August 2026. The company reported a 25 % increase in revenue, reaching $2.051 million, and an operating profit of $555 million compared with $548 million in the same period last year.
Revenue Drivers
The revenue rise was largely driven by royalty income from two key products:
- DARZALEX (a multiple‑myeloma therapy marketed by Johnson & Johnson)
- EPKINLY (an oral therapy for multiple myeloma, marketed by Novartis)
Royalty revenue grew by 24 % to $1.708 million. The company attributed this increase to higher sales of DARZALEX and Kesimpta, the latter being an immunotherapy for multiple sclerosis sold by Novartis.
Operating Expenses
Operating expenses rose by 28 % to $1.270 million, reflecting investment in research, development, and commercialization activities.
Guidance Update
Based on the first‑half performance, Genmab has raised its full‑year revenue and operating‑profit forecasts. Management highlighted the strong market uptake of DARZALEX and Kesimpta as a primary driver of the upward revision.
Market Reaction
Following the announcement, Genmab’s shares fell in the United States shortly after Danish market close, reflecting a short‑term profit‑taking move. In the Nordic market, the stock experienced modest volatility but remained within a narrow range.
Summary of Key Figures
| Item | First Half 2026 | YoY Change |
|---|---|---|
| Revenue | $2.051 million | +25 % |
| Operating profit | $555 million | +$7 million |
| Royalty income | $1.708 million | +24 % |
| Operating expenses | $1.270 million | +28 % |
Genmab’s results reinforce its position as a leading antibody‑based biopharmaceutical company and underline the importance of its partnership portfolio in driving revenue growth.
